Endogena Therapeutics, Inc. reposted this
Pharmaceutical giants, such as Swiss companies Roche and Novartis, are heavily investing in artificial intelligence (AI) to identify new drugs for various diseases. 🔬 But how accurate are AI predictions when drugs are tested in humans? We spoke with Gisbert SCHNEIDER, a professor of computer-assisted drug design at the Swiss federal institute of technology ETH Zürich, who used his AI models to identify molecules with a desired biological activity based on patterns in chemical structures. These became two drug candidates, one of which is in clinical trials. “I’m not sure we would have been able to find the drug candidate without AI,” said Matthias Steger PhD, MBA, who founded start-up Endogena Therapeutics, Inc. with Schneider. “Algorithms can see patterns that aren’t visible to the human eye.” AI’s potential to discover new drug candidates has fuelled an investment boom into AI start-ups and tech firms. Some studies suggest AI could reduce the time and cost of drug discovery by 25-50%. However, success on a computer screen doesn’t always translate to success in patients. “There is still a lot we don’t know about human biology, the evolution of disease and why some patients respond better to drugs than others,” Schneider told SWI. “There’s a tendency now to overhype the potential benefits of AI tools, because we forget this element of chaos when we interact with human biology.” Read the full story by our pharma and healthcare reporter Jessica Davis Pluess here. 👉 https://lnkd.in/eTqgYXvr InterAx Biotech Elif Ozkirimli #AI #artificialintelligence #deeplearning #drugdiscovery #swisspharma #innovation
Omar Khawaja
2mo
good insights Elif Ozkirimli, thanks for sharing.
Thank you for featuring us!